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Abstract
Purpose: Vessels with high venous flow rate are needed for the application of hemodialysis in patients needing chronic 
hemodialysis. The increase in the number of chronic hemodialysis patients has led to an increase in the number of 
vascular surgical operations. The aim of this study was to evaluate the results of polytetraflouroethylen (PTFE) graft 
arteriovenous fistula (AVF) applications.
Materials and Methods: Files of 596 patients who received hemodialysis treatment at the Nephrology Unit of the 
Şanlıurfa Mehmet Akif İnan State Hospital between September 2009 and 2013 were retrospectively analyzed. PTFE 
grafts and autogenous AVFs applied in 22 patients were analyzed, and demographic data and PTFE graft associated 
complications of these patients were evaluated.
Results: We found that the graft patency duration (months ± standard deviation) and the patency after graft revision 
were 16 ± 13 and 83.3%. Complications were detected in 14 patients (63%). One patient developed hematoma in 
early stages.
Conclusions: We conclude that even if PFTE graft AVF applications cause significant complications, the procedure 
has a high patency rate after graft revision.
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Introduction
Late phase kidney failure is a chronic disease that results 
from the accumulation of metabolic effluents in the body. 
The primary treatment is renal transplantation. In cases 
where renal transplantation cannot be applied, renal 
replacement treatment is the second choice.[1] Renal 
replacement treatment is being performed with hemodialysis 
and peritoneal dialysis. Hemodialysis is preferred over 
peritoneal dialysis since peritoneal dialysis has a high 
infection risk.[2] Vessels with high venous flow rate are 
needed for the application of hemodialysis in patients 
requiring chronic hemodialysis and the increase in the 
number of chronic hemodialysis patients has led to an 
increase in the number of vascular surgical operations.[3]
Today, autogenous arteriovenous fistula (AVF) created 
at the level of the wrist, described by Brescia–Cimino, is 
the method that is widely used in hemodialysis patients. 
Polytetraflouroethylen (PTFE) graft is being used in patients 
that lack appropriate venous access. Biological grafts can be 
used for hemodialysis access as well, but these have a higher 
complication rate.[2,4]
The first aim of this article is to share our experiences with 
graft complications. The second aim of the article is to 
present graft patency rates of patients where we applied a 
PTFE graft AVF with a retrospective evaluation.
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Materials and Methods
Files of 596 patients who were in the hemodialysis program 
of the Şanlıurfa Mehmet Akif İnan Training and Research 
Hospital between September 2009 and 2013 were analyzed. 
Ethics Committee approval was obtained from Harran 
University on 08.11.2013 with session 10 ruling 07. 
Twenty‑two patients (11 male; mean age 55 ± 21) with no 
chance of native vessel AVF, who received AVF treatment 
with PFTE were retrospectively evaluated.
The demographic data of these patients were recorded 
[Table 1]. Graft related complications, graft patency 
durations and mortality rates were also recorded [Table 2]. 
Arteriovenous graft complications were categorized 
in two groups: Early and late. Early complications 
refer to complications monitored during the surgical 
procedure or the day after the procedure and late refer 
to complications that were monitored after the 1st day 
of the procedure.
Specification of grafts
Grafts with a diameter of 6‑7 mm made of PTFE were 
used (Impra Carboflo, Cravley, UK). The lengths of the 
grafts varied in accordance with the position of the graft 
and the need. Patencies and flow rates of the of PTFE grafts 
were controlled with ultrasonography (Mindray Model: 
UMT‑200, Hamburg, Germany) from distal and proximal 
anastomosis area. The position of the application, target 
vessels and graft choices were determined in light of the 
data from the ultrasonography.
Antibiotic prophylaxis was done with sefalozine sodium 1 h 
before the operation in every case. All of the cases were 
operated in an elective position, in a sterile surgery room and 
under local anesthesia (Prilokaine, Citanest, AstraZeneca, 
Germany). After the incisions, first we explored and suspended 
to the arteria and vein. 50‑100 units of unfractionated heparin 
were given to all patients before vascular clamp. The grafts 
were used after being washed with 5000 units of heparinized 
SF. A radio‑basilic front arm loop AVF was applied to one, 
femoral arteria‑femoral vein fistula in the thigh position in 
the case of one patient; brachioaxillary AVF was applied to all 
of the other patients. Anastomosis were performed with 6/0 
prolene end to side anastomosis technique. When the thrill 
were received from anastomosis after the surgery the procedure 
were ended. After placing the graft into position, antibiotic 
prophylaxis was prolonged for an extra 24 h using intravenous 
cafalosizine sodium. With regards to early complications, the 
patients were monitored for 24 h and treated in case of need. 
The control Ultrasonography of the patients was taken after 
the operation and when discharged from the hospital. During 
discharge, 100 mg/day acetylsalicylic acid was added to their 
treatment. After a week of graft maturation, use of grafts for 
dialysis was allowed.
Statistical analysis
SPSS 15.0 (SPSS, Chicago, IL, USA) was used in the 
evaluation of the results. Data are given as mean ± standard 
deviation.
Results
Data from 22 patients were analyzed in this study. The mean 
age of the patients was 55 (minimum = 15, maximum = 80) 
and 11 of them were male. In the 4‑year period of this 
study, AVF was applied to 596 patients. Among these 
patients, the PFTE graft usage rate was 3.6%. The follow‑up 
time of the cases varied between 1 and 48 months. 
Radio‑basilic front arm loop AVF was applied to one 
patient, femoral arteria‑femoral vein in the leg position 
to one patient and brachio‑axillary AVF was applied to 
20 patients. Complications were detected in 14 patients 
with grafts (63%). In one patient, early complications 
were bleeding and hematoma. Late complications were 
monitored in 13 patients. The most frequent type of 
late complication was graft thrombosis, which was seen 
in 12 patients (54%) [Figure 1]. Other complications 
were, in order of decreasing frequency, graft infection in 
3 cases (13%) [Figure 2], graft aneurysm in 2 (9%), late 






Coronary heart disease (%) 27.03
Duration of dialysis (months±SD) 43±24
SD=Standard deviation; DM=Diabetes mellitus
Table 2: Complication rates in patients and clinical 
characteristics
Parameters n Patient
Early bleeding (%) 22 4.5
Early hematoma (%) 22 4.5
Early trombosis (%) 22 0
Late bleeding (%) 22 9.1
Late hematoma (%) 22 4.5
Late trombosis (%) 22 54.5
Aneurysm (%) 22 9.1
Arteriovenous fistula infection (%) 22 13.6
Graft patency duration (months±SD) 22 16±13
Patency after graft revision (%) 12 83.3
Revision and embolectomy execution time (months±SD) 12 12±11
Patency after embolectomy (months±SD) 10 5±3
Permanent catheter (%) 22 36.4
General mortality (%) 22 27.3
Mortality due to PTFE graft 22 4.5
SD=Standard deviation; PTFE=Polytetraflouroethylen
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bleeding in 2 (9%) [Figure 3] and late hematoma in 1 (4.5%) 
patient. Mortality was observed in six patients (27.3%) 
during follow‑up in the study. Graft dependent mortality 
was seen in one patient after aneurysm rupture.
Discussion
According to a 2011 report, the number of patients receiving 
renal replacement treatment due to renal failure in Turkey 
was 60,443. Hemodialysis was predominant (83.6%) being 
performed for renal replacement treatment. According 
to the same report, arteriovenous graft was being used in 
2.8% of the patients.[5] As a result of our 4‑year period 
retrospective study, we found that the PTFE graft rate of 
use was 3.6%, which is close to the data from the Health 
Ministry. Süleymanlar et al. reported that the main causes 
of chronic renal failure were diabetes mellitus (DM) (32%) 
and hypertension (HT) (28%).[5] In this study group, we 
observed DM in 45% and HT in 54% of patients. Turan et al. 
showed that HT and DM was observed with a percentage 
of 61% in venous thrombosis complication in autogenous 
AVF treated group.[6] We observed 58% DM and 75% HT 
in the patients that had PTFE graft thrombosis, and we 
can conclude that the results are consistent with previous 
studies.
Many complications can be seen due to AVF treatment for 
hemodialysis, such as venostasis, infection, pseudoaneurism 
and finger amputation.[7] It has been shown that stenosis 
and thrombosis are the most prevalent complications in the 
hemodialysis access path.[8‑10] In the data from our study, we 
found graft thrombosis to be the main complication (54%). 
Odabaşı et al., stated that thrombosis and infection were the 
most prevalent complications in their study.[9] Raju reported 
64% thrombosis, 35% infection, 16% pseudoaneurism and 
3% steal.[3]
In the present study, we observed complications in 14 
of the patients (63%). We also observed hematoma and 
bleeding at the incision line as an early complication 
in one patient. We drained the hematoma and brought 
the bleeding under control. Other complications 
occurred at a later stage. Thrombosis was detected in 
PTFE graft AVF in 12 patients (54%). We found that 
the PTFE graft AVF thrombosis was at the earliest 
in the 1st month and the latest in the 36th month. 
We performed thrombectomy for all the thrombosed 
grafts, and the procedure was not successful for two 
patients. Graft patency was later done for 10 patients. 
Başel  et al. showed graft thrombosis was the most 
common complication in a group of 1043 patients that 
were treated with graft AVF. It has also been shown 
that patency was obtained in only 36% of patients 
after surgical revision to the thrombosed AVF.[10] In 
a  study  of  20  patients,  Odabaşı  et al. observed 85% 
graft thrombosis in PTFE AVF patients. They also 
reported a 70% patency after revision. In our study, 
the graft thrombosis rate was 54% in PTFE graft AVF 
patients. Patency after revision thrombectomy was 83% 
and patency continuum duration was between 2 and 
12 months after thrombectomy.
In the light of the data given, in cases of thrombosis, PTFE 
grafts respond better to thrombectomy and revision than 
Figure 1: Late complication graft thrombosis materials
Figure 2: Graft infection with skin erosion
Figure 3: Late	bleeding	in	graft	İnfection
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autogenous AVFs. The second common complication is 
graft infection (13%). We observed infection in three 
patients. Graft resection was performed, and a permanent 
hemodialysis catheter was inserted for two of these 
patients. The other patient was treated with intravenous 
antibiotics and medical dressing. Graft aneurysm was seen 
in two patients (9%) and graft resection was performed. 
A permanent hemodialysis catheter was inserted for one 
of the patients and the other patient, then he died from 
aneurysm rüptür and bleeding. In two patients, there 
was bleeding at the hemodialysis needle access site in 
the late stage. Both of these patients were operated. The 
bleeding was stopped with a 7‑0 prolene. Mortality was 
seen in six patients (27.3%) during follow‑up. Chronic 
kidney failure occurred in two patients, heart failure 
in two patients, mortality due to sepsis in one patient 
and mortality due to graft aneurysm rupture was also 
observed.
Conclusion
The higher rate of complications in patients that have 
a PTFE graft AVF in comparison to patients with an 
autogenous AVF can be considered as a disadvantage, but 
it provides an early hemodialysis access path and a higher 
rate of patency after graft thrombosis, which is an advantage. 
Even though autogenous AVF is primarily recommended, 
AVF using PTFE can be preferred for hemodialysis access 
if there are no other alternatives.
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